Triple

T15982896
Position Surface form Disambiguated ID Type / Status
Subject Vertex Pharmaceuticals E387617 entity
Predicate brandName P1500 FINISHED
Object Trikafta
Trikafta is a breakthrough combination therapy for cystic fibrosis that targets the underlying genetic defect to improve lung function and reduce symptoms in eligible patients.
 E1188104 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Trikafta | Statement: [Vertex Pharmaceuticals, brandName, Trikafta]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Trikafta
Context triple: [Vertex Pharmaceuticals, brandName, Trikafta]
  • A. Evrysdi
    Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
  • B. Biktarvy
    Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
  • C. Vitrakvi
    Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
  • D. Skyrizi
    Skyrizi is a prescription biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease by targeting the interleukin-23 (IL-23) pathway.
  • E. Singulair
    Singulair is a prescription leukotriene receptor antagonist (montelukast) commonly used to prevent and manage asthma and allergy symptoms.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Trikafta
Triple: [Vertex Pharmaceuticals, brandName, Trikafta]
Generated description
Trikafta is a breakthrough combination therapy for cystic fibrosis that targets the underlying genetic defect to improve lung function and reduce symptoms in eligible patients.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Trikafta
Target entity description: Trikafta is a breakthrough combination therapy for cystic fibrosis that targets the underlying genetic defect to improve lung function and reduce symptoms in eligible patients.
  • A. Evrysdi
    Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
  • B. Biktarvy
    Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
  • C. Vitrakvi
    Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
  • D. Skyrizi
    Skyrizi is a prescription biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease by targeting the interleukin-23 (IL-23) pathway.
  • E. Singulair
    Singulair is a prescription leukotriene receptor antagonist (montelukast) commonly used to prevent and manage asthma and allergy symptoms.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d86da94ccc819083d187f5dc6a123e completed April 10, 2026, 3:25 a.m.
NER Named-entity recognition batch_69e15755b5548190acfa29eecb11e675 completed April 16, 2026, 9:40 p.m.
NED1 Entity disambiguation (via context triple) batch_69ffc3cdf7848190848e9081027dc027 completed May 9, 2026, 11:31 p.m.
NEDg Description generation batch_69ffc5669c1c81909bacf61c96cb7816 completed May 9, 2026, 11:38 p.m.
NED2 Entity disambiguation (via description) batch_69ffc5c7db1c8190b4e1de6f6e3ce8a0 completed May 9, 2026, 11:39 p.m.
Created at: April 10, 2026, 4:54 a.m.